GLP-1 medications: a complete guide for 2026

If you have been researching weight loss medications, you have probably encountered the term GLP-1. These medications have become the most significant development in obesity treatment in decades — and for good reason. They work, they are backed by rigorous clinical trials, and they are now more accessible than ever.

This guide covers everything you need to know about GLP-1 medications in 2026: what they are, how they work, the FDA-approved options, what results to expect, side effects, insurance coverage, and how to choose the right provider. It is written for patients considering treatment, not for clinicians. No jargon. No hype. Just the information you need to make an informed decision.

What are GLP-1 medications?

GLP-1 stands for glucagon-like peptide-1. It is a hormone your body produces naturally, part of a family of hormones called incretins. When you eat, your gut releases GLP-1, which signals to your brain that you are full and helps regulate blood sugar.

GLP-1 receptor agonists are medications that mimic this natural hormone — but at higher, more sustained levels than your body produces on its own. The result is a meaningful reduction in appetite, slower gastric emptying (food stays in your stomach longer, so you feel full longer), and improved blood sugar regulation.

These medications were originally developed for type 2 diabetes. Researchers noticed that patients taking them for blood sugar control were also losing significant amounts of weight. This led to clinical trials specifically for weight management, and eventually to FDA approval of dedicated weight loss formulations.

How GLP-1 medications work

GLP-1 medications work through three main mechanisms, each targeting a different part of your body. Together, they create a combined effect on appetite, digestion, and metabolism.

Brain: appetite reduction

GLP-1 medications act on receptors in the hypothalamus — the part of your brain that regulates hunger and satiety. They reduce the intensity of hunger signals and increase the feeling of satisfaction after eating. Patients consistently describe this as a reduction in food noise: the constant background thinking about food, cravings, and urges to eat.

This is not willpower. It is biochemistry. The medication changes the signals your brain receives about hunger, making it genuinely easier to eat less without feeling deprived.

Stomach: slower emptying

GLP-1 medications slow gastric emptying — the rate at which food moves from your stomach into your small intestine. This means food stays in your stomach longer, and you feel full for a longer period after eating. A meal that might have kept you satisfied for two hours may now keep you comfortable for four or five.

This is also why nausea is the most common side effect, particularly during dose increases. Your stomach is adjusting to a new pace of digestion. For most patients, this adjustment period is temporary.

Pancreas: insulin regulation

GLP-1 medications improve your body’s insulin response, particularly after meals. They stimulate insulin release when blood sugar is high and reduce glucagon (a hormone that raises blood sugar) when it is not needed. This helps maintain stable blood sugar levels, which reduces energy crashes and the reactive hunger that often follows blood sugar dips.

FDA-approved GLP-1 medications for weight loss

As of early 2026, there are two GLP-1 medications with specific FDA approval for chronic weight management in adults. Understanding the distinction between weight loss approval and diabetes approval matters — it affects insurance coverage, dosing, and how the medication is prescribed.

Wegovy (semaglutide 2.4mg)

Wegovy is manufactured by Novo Nordisk and received FDA approval for weight management in June 2021. It is a once-weekly injection of semaglutide at a maintenance dose of 2.4mg. Wegovy is approved for adults with a BMI of 30 or greater, or adults with a BMI of 27 or greater who have at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol).

Wegovy was studied in the STEP clinical trial program, where patients lost an average of 14.9% of body weight over 68 weeks (STEP 1). It also received a supplemental FDA approval based on the SELECT cardiovascular outcomes trial, which showed a reduction in major cardiovascular events in patients with obesity and established cardiovascular disease.

Zepbound (tirzepatide)

Zepbound is manufactured by Eli Lilly and received FDA approval for weight management in November 2023. It is a once-weekly injection of tirzepatide, which is a dual-action medication targeting both GLP-1 and GIP receptors. Zepbound carries the same BMI eligibility criteria as Wegovy.

Zepbound was studied in the SURMOUNT clinical trial program. The dual receptor mechanism provides effects through both incretin pathways, which may account for some differences in outcomes compared to single-receptor medications.

Wegovy vs. Zepbound

Both Wegovy and Zepbound are effective, FDA-approved weight loss medications. But they are not identical. Here are the key differences that matter for patients:

Mechanism of action

Wegovy is a GLP-1 receptor agonist. It targets one hormone receptor. Zepbound is a GLP-1/GIP dual receptor agonist. It targets two hormone receptors. The dual mechanism may provide additional metabolic benefits beyond what GLP-1 alone offers, though both approaches are clinically effective.

Clinical trial results

The STEP trials showed ~15% weight loss with Wegovy (STEP 1, 68 weeks). The SURMOUNT trials showed ~22.5% with Zepbound (SURMOUNT-1, 72 weeks). Direct comparison between trial programs requires caution because the patient populations and study designs were not identical. The SURMOUNT-5 head-to-head trial confirmed tirzepatide produced greater weight loss than semaglutide (20.2% vs. 13.7% over 72 weeks).

Side effect profiles

Both medications share similar GI-related side effects: nausea, diarrhea, constipation, and vomiting. These are most common during dose titration and typically resolve over time. The overall tolerability profiles are comparable, though individual responses vary.

Insurance coverage

Coverage varies significantly by plan. Some insurers cover Wegovy but not Zepbound, or vice versa. Some cover neither, and some cover both but with different tier placements or prior authorization requirements. Wegovy’s cardiovascular indication from the SELECT trial has opened additional coverage pathways that are not yet available for Zepbound.

What results to expect

One of the most important things to understand about GLP-1 medications is that results are not immediate. These are not crash diets or quick fixes. They are treatments that produce gradual, sustained weight loss over months, which is exactly what makes them effective long-term.

Weight loss timeline

Most patients begin to notice changes within the first four to eight weeks of treatment, during the early titration phase. However, the majority of weight loss typically occurs between months three and twelve, as you reach the full maintenance dose and your body fully responds to the medication.

• Months 1–3: Gradual dose increases. Early appetite reduction. Most patients see initial weight loss during this phase, though the primary focus is building tolerance.
• Months 3–6: You are approaching or have reached the maintenance dose. Weight loss accelerates for most patients during this period.
• Months 6–12: Continued weight loss, typically at a slowing rate. Many patients approach their maximum weight loss during this window.
• Month 12+: Weight maintenance. The goal shifts to sustaining results through continued medication use alongside dietary and lifestyle habits.

Realistic expectations

Clinical trials provide averages, and averages can be misleading. Not every patient will achieve the same results. Factors that influence outcomes include your starting weight, metabolic health, adherence to the medication, dietary habits, and physical activity level.

What is consistent across almost all patients is that GLP-1 medications, combined with lifestyle modifications, produce significantly more weight loss than lifestyle modifications alone. The medication provides a biological advantage that makes the behavioral changes more achievable and more effective.

Common side effects

Side effects are a normal part of GLP-1 treatment, particularly during the dose titration phase. Understanding what to expect — and when to be concerned — helps you manage the adjustment period with confidence.

Nausea

Nausea is the most commonly reported side effect across both Wegovy and Zepbound. It is a direct result of slower gastric emptying. For most patients, nausea is mild to moderate, occurs primarily during the first one to two weeks at each new dose level, and resolves as your body adjusts.

There are well-established strategies for managing nausea: eating smaller, more frequent meals; avoiding high-fat and greasy foods; staying hydrated with small sips; and trying ginger-based remedies. If nausea is severe, your clinician can prescribe anti-nausea medication or adjust your titration schedule.

Other GI effects

• Diarrhea. Reported by some patients, usually mild and temporary. Staying hydrated is important.
• Constipation. Can occur as digestion slows. Adequate fiber intake, hydration, and physical activity help.
• Vomiting. Less common than nausea. If persistent, contact your care team.
• Abdominal discomfort. Mild bloating or stomach discomfort is common during titration and typically resolves.

Injection site reactions

Both Wegovy and Zepbound are administered via subcutaneous injection. Some patients experience mild redness, swelling, or itching at the injection site. These reactions are typically minor and resolve within a day or two. Rotating injection sites (abdomen, thigh, upper arm) helps minimize these effects.

What’s new in 2026

GLP-1 treatment has changed significantly over the past year. Here are the most important developments for patients considering or currently on treatment.

Oral semaglutide for obesity

One of the most anticipated developments arrived in late 2025: an oral formulation of semaglutide approved for weight management. This provides an alternative for patients who prefer not to take weekly injections. The oral version requires specific dosing instructions — it must be taken on an empty stomach with a small amount of water, and you must wait at least 30 minutes before eating or drinking anything else. But for patients who find injections to be a barrier, this is a meaningful option.

Expanding insurance coverage

Insurance coverage for GLP-1 weight loss medications has continued to expand. More commercial plans are adding coverage, and the Medicare coverage picture is evolving. Wegovy’s cardiovascular indication has been particularly impactful, creating additional pathways for coverage approval. The trend is clearly toward broader access, though significant variability between plans remains.

Supply stabilization

The widespread shortages that affected both Wegovy and Zepbound through 2023 and 2024 are resolved. Both manufacturers invested heavily in expanded production capacity, and all dose strengths are now available at most pharmacies.

Long-term outcomes data

We now have longer-term data on both semaglutide and tirzepatide, including evidence on weight maintenance, cardiovascular outcomes, and safety over extended treatment periods. This growing body of evidence reinforces the safety and efficacy of these medications for long-term use, which is important because obesity is a chronic condition that typically requires ongoing management.

Insurance and cost

Cost is one of the most common concerns patients have about GLP-1 medications. Without insurance, the list price of these medications is significant. But the out-of-pocket reality is more nuanced — and often more favorable — than the headline numbers suggest.

Who covers what

Insurance coverage for GLP-1 weight loss medications varies widely by plan type, employer, and state. In general, the trend is toward broader coverage, but the details matter:

• Commercial/employer plans: Many now cover Wegovy, Zepbound, or both, though prior authorization is almost always required. Your plan’s formulary determines which medication is preferred and at what tier.
• Medicare: Coverage rules are evolving. The traditional Medicare prohibition on weight loss medications has been challenged by legislative and regulatory developments. Check current eligibility with your provider.
• Medicaid: Coverage varies significantly by state. Some state Medicaid programs cover GLP-1 medications for weight management; many do not.

Prior authorization

Almost all insurance plans require prior authorization for GLP-1 weight loss medications. This means your provider must submit documentation to your insurer demonstrating medical necessity — typically including your BMI, weight-related conditions, and evidence of previous weight management attempts. A provider experienced with these medications will know what your specific plan requires and how to submit a strong authorization request.

Manufacturer savings programs

Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) offer manufacturer savings programs that can significantly reduce out-of-pocket costs for eligible patients with commercial insurance. These programs can reduce copays substantially. Eligibility and terms change, so ask your provider about current options.

Choosing a provider

Where you get your GLP-1 medication matters as much as which medication you take. The quality of clinical oversight, ongoing monitoring, and support services varies enormously between providers. Here is what to look for — and what to avoid.

What to look for

• FDA-approved medications only. Your provider should prescribe Wegovy, Zepbound, or other FDA-approved formulations — not compounded semaglutide or tirzepatide. Compounded versions are not subject to the same manufacturing standards, purity testing, or dosing consistency as FDA-approved products.
• Clinical oversight. You should have a board-certified clinician overseeing your treatment — not just writing a prescription. This means regular check-ins, lab monitoring when appropriate, and the ability to adjust your treatment plan as needed.
• Dietitian or nutrition support. The best outcomes come from combining medication with structured dietary guidance. A provider that offers access to registered dietitians or structured nutrition programs is a strong signal of a full approach.
• Insurance navigation. Prior authorization, appeals, manufacturer savings programs — managing GLP-1 insurance coverage is complex. A good provider handles this for you.

Warning signs

• Providers offering compounded semaglutide or tirzepatide as a cheaper alternative to FDA-approved medications.
• No in-person or video evaluation before prescribing.
• No ongoing monitoring or follow-up plan.
• Pressure to start at a high dose or skip the titration schedule.
• Claims that sound too good to be true about guaranteed results or timelines.

Starting treatment

If you are considering GLP-1 medication, here is what the process typically looks like from your first visit through the initial months of treatment.

Your first visit

Your initial consultation involves a full health evaluation. Your clinician will review your medical history, current medications, weight history, and weight-related conditions. They will discuss your goals and determine whether a GLP-1 medication is appropriate for you. If it is, they will recommend a specific medication based on your health profile, insurance coverage, and preferences.

This visit is also where you learn the practical details: how to administer the injection, where to inject, how to store the medication, and what to expect during the first weeks of treatment.

The titration phase

Both Wegovy and Zepbound use a gradual dose titration schedule. You start at a low dose and increase every four weeks until you reach the full maintenance dose. This gradual approach minimizes side effects and allows your body to adjust. The full titration from starting dose to maintenance dose takes approximately 16–20 weeks, depending on the medication.

During titration, your care team monitors your response: How is your appetite changing? Are you experiencing side effects? Is your weight trending in the right direction? Are your labs stable? This is active clinical management, not a set-it-and-forget-it prescription.

Ongoing monitoring

Once you reach maintenance dose, ongoing monitoring continues. Regular check-ins with your care team ensure that the medication remains effective, side effects are managed, and your overall health is on track. Weight management is a long-term endeavor, and the support should be long-term as well.

Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.

Medication labeling reminder: Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes only. For weight management, the FDA-approved options are Wegovy (semaglutide) and Zepbound (tirzepatide).

The PEAK Clinical Team

PEAK Wellness & Aesthetics

Evidence-based guidance from our board-certified clinicians specializing in medical weight loss and obesity medicine.